The Next Generation Of mRNA Products: Implications For Quality Control

The emergence of mRNA as a therapeutic modality has caused a transformative shift in the biopharmaceutical industry. mRNA has been crucial in tackling global health challenges like the COVID-19 pandemic and has opened new avenues in vaccines, therapeutics, and personalized medicine. Looking ahead, the potential of mRNA will be driven by regulatory, business, and scientific factors. Additionally, the technologies supporting mRNA-based products will evolve exponentially both in breadth and complexity. As a result, these emerging technologies will significantly impact the analytical development, product characterization, and biosafety testing of mRNA products. To fully realize the potential of mRNA as a therapeutic or vaccine modality, biopharma developers must employ cutting-edge analytical methods to ensure the safety and efficacy of these products.